Unicycive Therapeutics Inc (UNCY)

$5.05 -0.18 (-3.44%)
Market Cap 143.27M
Revenue (ttm) 0.00
Net Income (ttm) -26.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 565,900
Avg Vol 1,716,276
Day's Range N/A - N/A
Shares Out 27.39M
Stochastic %K 43%
Beta 1.79
Analysts Strong Sell
Price Target $34.89

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 351 4495
Address:
1975 West El Camino Real, Suite 204, Mountain View, United States
erictwin1
erictwin1 Aug. 7 at 3:18 AM
$UNCY Bought more today, price averaging my cost. when it finally pops i will be a very happy guy💰💰💰 So just buy more shares people
0 · Reply
KirkHanna
KirkHanna Aug. 7 at 2:10 AM
$UNCY Citi group and Bank of New York purchased
0 · Reply
Logmart939
Logmart939 Aug. 7 at 1:11 AM
$UNCY bet the shorts are gonna flood in this 3rd time. Gonna make for one hell of a short squeeze.
0 · Reply
BioRich
BioRich Aug. 6 at 4:23 PM
$UNCY What are we thinking? $7 on Inspection? Or higher? Looks like a lot of Regulatory milestone on the horizon that can re-rate this. Cheers!
4 · Reply
Legendary_Scoober
Legendary_Scoober Aug. 6 at 3:36 PM
$UNCY planning to resubmit in q3…it’s going to be 2027 before this is back over $6.
1 · Reply
Eire32
Eire32 Aug. 6 at 2:59 AM
$UNCY earnings deadline is August 15th so hopefully they can update us by then .
0 · Reply
Eire32
Eire32 Aug. 5 at 8:56 PM
$UNCY earnings call today. Schoppe took the time to mention UNCY “The partner is working very closely with US FDA on the recent CRL… and we are working closely with our partner for next steps.
2 · Reply
Eire32
Eire32 Aug. 5 at 4:03 PM
$UNCY anyone that may be interested Schilpa Medicare who is the manufacturing partner for UNCY just released their earnings report this morning and they mentioned OLC drug. The earnings call is after market close today so they may mention it again. https://www.bseindia.com/xml-data/corpfiling/AttachLive/fab43b0e-31f7-4565-8197-60d8aa5dba4a.pdf
1 · Reply
ccledez
ccledez Aug. 5 at 3:19 PM
$UNCY not that it really matters But Gemini states the most likely to report positive news are now (just the order) Uncy 1st $CING 2nd $GRCE 3rd 😂
0 · Reply
ccledez
ccledez Aug. 5 at 2:08 PM
$UNCY about freaking time!!!
0 · Reply
Latest News on UNCY
Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

2026-07-01T13:45:11.000Z - 5 weeks ago

Unicycive Therapeutics price target lowered to $50 from $60 at Noble Capital

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

2026-07-01T12:50:20.000Z - 5 weeks ago

Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Jun 30, 2026, 12:51 PM EDT - 5 weeks ago

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

2026-06-30T16:35:10.000Z - 5 weeks ago

Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

2026-06-30T14:50:20.000Z - 5 weeks ago

Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

2026-06-30T11:25:41.000Z - 5 weeks ago

Unicycive Therapeutics receives complete response letter from FDA for OLC NDA

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Jun 30, 2026, 7:05 AM EDT - 5 weeks ago

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

Unicycive Therapeutics Proxy statement: Proxy filing

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Unicycive Therapeutics Proxy statement: Proxy filing

Unicycive Therapeutics files $150M mixed securities shelf

2026-06-05T20:20:10.000Z - 2 months ago

Unicycive Therapeutics files $150M mixed securities shelf

Unicycive Therapeutics Registration statement: Registration filing

Jun 5, 2026, 8:00 AM EDT - 2 months ago

Unicycive Therapeutics Registration statement: Registration filing

Unicycive Therapeutics Slides: Corporate presentation

Jun 4, 2026, 7:00 AM EDT - 2 months ago

Unicycive Therapeutics Slides: Corporate presentation

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

2026-06-02T13:07:41.000Z - 2 months ago

Unicycive Therapeutics price target raised to $18 from $15 at Benchmark

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:27 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:26 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:25 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics Earnings release

Jun 1, 2026, 10:24 AM EDT - 2 months ago

Unicycive Therapeutics Earnings release

Unicycive Therapeutics management to meet virtually with Piper Sandler

2026-05-28T15:05:39.000Z - 2 months ago

Unicycive Therapeutics management to meet virtually with Piper Sandler

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

2026-05-13T11:14:54.000Z - 3 months ago

Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim

Unicycive Therapeutics Slides: Company presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Unicycive Therapeutics Slides: Company presentation

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

2026-05-12T11:51:45.000Z - 3 months ago

Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:05 AM EDT - 3 months ago

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics initiated with a Buy at B. Riley

2026-05-01T14:07:09.000Z - 3 months ago

Unicycive Therapeutics initiated with a Buy at B. Riley

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 3:45 PM EDT - 4 months ago

Unicycive Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 9, 2026, 7:05 AM EDT - 4 months ago

Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

2026-04-06T11:30:08.000Z - 4 months ago

Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

2026-04-02T10:59:29.000Z - 4 months ago

Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 7:05 AM EDT - 4 months ago

Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

Unicycive Therapeutics management to meet with Piper Sandler

2026-02-20T14:22:23.000Z - 5 months ago

Unicycive Therapeutics management to meet with Piper Sandler

Unicycive Therapeutics initiated with a Buy at WestPark Capital

2026-02-19T12:57:38.000Z - 6 months ago

Unicycive Therapeutics initiated with a Buy at WestPark Capital

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 17, 2026, 9:15 AM EST - 6 months ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Feb 4, 2026, 7:05 AM EST - 6 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 9:15 AM EST - 6 months ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

2026-01-29T12:15:28.000Z - 6 months ago

Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 6 months ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

2025-12-29T12:10:32.000Z - 7 months ago

Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 29, 2025, 7:05 AM EST - 7 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Dec 1, 2025, 1:41 PM EST - 8 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 25, 2025, 7:05 AM EST - 9 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:05 AM EST - 9 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:05 AM EST - 9 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 30, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Oct 28, 2025, 7:05 AM EDT - 10 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Aug 26, 2025, 7:00 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Aug 18, 2025, 7:05 AM EDT - 1 year ago

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

erictwin1
erictwin1 Aug. 7 at 3:18 AM
$UNCY Bought more today, price averaging my cost. when it finally pops i will be a very happy guy💰💰💰 So just buy more shares people
0 · Reply
KirkHanna
KirkHanna Aug. 7 at 2:10 AM
$UNCY Citi group and Bank of New York purchased
0 · Reply
Logmart939
Logmart939 Aug. 7 at 1:11 AM
$UNCY bet the shorts are gonna flood in this 3rd time. Gonna make for one hell of a short squeeze.
0 · Reply
BioRich
BioRich Aug. 6 at 4:23 PM
$UNCY What are we thinking? $7 on Inspection? Or higher? Looks like a lot of Regulatory milestone on the horizon that can re-rate this. Cheers!
4 · Reply
Legendary_Scoober
Legendary_Scoober Aug. 6 at 3:36 PM
$UNCY planning to resubmit in q3…it’s going to be 2027 before this is back over $6.
1 · Reply
Eire32
Eire32 Aug. 6 at 2:59 AM
$UNCY earnings deadline is August 15th so hopefully they can update us by then .
0 · Reply
Eire32
Eire32 Aug. 5 at 8:56 PM
$UNCY earnings call today. Schoppe took the time to mention UNCY “The partner is working very closely with US FDA on the recent CRL… and we are working closely with our partner for next steps.
2 · Reply
Eire32
Eire32 Aug. 5 at 4:03 PM
$UNCY anyone that may be interested Schilpa Medicare who is the manufacturing partner for UNCY just released their earnings report this morning and they mentioned OLC drug. The earnings call is after market close today so they may mention it again. https://www.bseindia.com/xml-data/corpfiling/AttachLive/fab43b0e-31f7-4565-8197-60d8aa5dba4a.pdf
1 · Reply
ccledez
ccledez Aug. 5 at 3:19 PM
$UNCY not that it really matters But Gemini states the most likely to report positive news are now (just the order) Uncy 1st $CING 2nd $GRCE 3rd 😂
0 · Reply
ccledez
ccledez Aug. 5 at 2:08 PM
$UNCY about freaking time!!!
0 · Reply
900fix
900fix Aug. 5 at 1:40 PM
$UNCY Dragging out just like the last CRL. Gupta is good at this. Come back next year. He should have been shown the door last CRL.
2 · Reply
bpm78
bpm78 Aug. 4 at 11:31 PM
$UNCY @Eire32 See the crl snip from 2025 and 2026 respectively where fda still calling for responses on the deficiencies on the form 483.
2 · Reply
buymoremakemore
buymoremakemore Aug. 4 at 11:14 PM
$UNCY https://x.com/crypto_biotech/status/2060337305378804179?s=20 This would be cool!
1 · Reply
Logmart939
Logmart939 Aug. 4 at 9:50 PM
$UNCY and just like that we lost all of today’s gains
2 · Reply
BLtheKid
BLtheKid Aug. 4 at 7:06 PM
$UNCY amazing how five weeks have gone by since the recent fiasco and there is been no update at all from the company since then, with the bonus of having the market go completely wild and this not participate to even the tiniest degree
2 · Reply
buymoremakemore
buymoremakemore Aug. 4 at 3:47 PM
$UNCY Just bought 15k shares. Seems like those willing to be wait will be rewarded. Inspection PR and the party begins
1 · Reply
Merlintrader
Merlintrader Aug. 4 at 9:35 AM
Unicycive Therapeutics (Nasdaq: $UNCY) Stock Hub: OLC, the Second FDA CRL, Manufacturing Risk and the Road Back https://www.merlintrader.com/unicycive-therapeutics-stock-hub/
0 · Reply
BLtheKid
BLtheKid Aug. 3 at 8:02 PM
$UNCY massive MM manipulation into the close to take away most of the day's gain in about twenty minutes. that's how they continue to accumulate for themselves or their clients. just repeat the same process everyday, drop it early to try to get people out on the downside and then they have no choice but to raise the price most of the day in order to get any shares at all. then throw a few shares at it EOD to try to reset the price lower and get another crack at accumuating a few more down here in the sub-basement tomorrow.
1 · Reply
MAVman
MAVman Aug. 3 at 5:10 PM
$UNCY
0 · Reply
zawojak
zawojak Aug. 3 at 6:50 AM
$UNCY Who's ready for final round 3 ?
2 · Reply
BioRich
BioRich Aug. 3 at 4:22 AM
$SLS For those that didn't see what @ExitLiquidity was referring to, here's my Top 5 Bio Roster Spots for the month of August: 1) $RGNX 2) $KYTX 3) MLTX 4) $UNCY 5) $BIOA Who do you have?
4 · Reply
Logmart939
Logmart939 Aug. 2 at 11:55 PM
$UNCY so am I the only one that’s expecting news of a inspection? Wouldn’t they need to submit the NDA before they can have a inspection since the time between the NDA and approval the inspection happens?
2 · Reply